Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease
[Background & Aims] Current guidelines recommend a two-step approach for risk stratification in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) involving Fibrosis-4 index (FIB-4) followed by liver stiffness measurement (LSM) by vibration-controlled transient elasto...
| Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2025 |
| País: | España |
| Institución: | Consejo Superior de Investigaciones Científicas (CSIC) |
| Repositorio: | DIGITAL.CSIC. Repositorio Institucional del CSIC |
| OAI Identifier: | oai:digital.csic.es:10261/400656 |
| Acceso en línea: | http://hdl.handle.net/10261/400656 https://api.elsevier.com/content/abstract/scopus_id/105000575199 |
| Access Level: | acceso abierto |
| Palabra clave: | FIB-4 Hepatocellular carcinoma MASLD VCTE Hepatic decompensation |
| Sumario: | [Background & Aims] Current guidelines recommend a two-step approach for risk stratification in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) involving Fibrosis-4 index (FIB-4) followed by liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) or similar second-line tests. This study aimed to examine the prognostic performance of this approach. |
|---|